SCHEDULE: Roger M. Perlmutter Discloses 5.2% Stake in Eikon
Beneficial Ownership Disclosure
Dr. Roger M. Perlmutter has filed a Schedule 13G reporting beneficial ownership of 5.2% of Eikon Therapeutics, Inc. common stock.
Summary
- Dr. Roger M. Perlmutter reports beneficial ownership of 2,893,171 shares of Eikon Therapeutics, Inc.
- The stake represents 5.2% of the company's outstanding common stock.
- Holdings include 1,190,999 shares of common stock, 1,417,315 shares underlying options exercisable within 60 days, and 284,857 shares held via Perlmutter Consulting, Inc.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing insider ownership levels rather than a new strategic development.
Positives
- Significant insider alignment with 5.2% ownership stake.
- Includes substantial exercisable option holdings, indicating long-term commitment.
Negatives
- None identified in this regulatory disclosure.
Risks
- Concentration of voting power in a single individual.
- Market volatility associated with biotech equity holdings.
Future Outlook
Not applicable as this is a beneficial ownership disclosure filing.
Industry Context
StockSavvy.ai notes that Schedule 13G filings by key industry figures in biotech often signal confidence in the company's long-term pipeline and strategic direction, particularly when involving significant option-based holdings.
Comparison to Industry Standards
- The filing follows standard SEC requirements for reporting beneficial ownership exceeding 5% of a class of equity securities.
- The disclosure of both direct shares and exercisable options is consistent with standard reporting practices for corporate insiders.
Related Party Transactions
- Disclosure of 284,857 shares held by Perlmutter Consulting, Inc., where Dr. Perlmutter is the president and sole shareholder.
Stakeholder Impact
- Provides transparency to shareholders regarding the concentration of voting power.
Next Steps
- Future filings if ownership percentage changes significantly.
Key Dates
| Date | Description |
|---|---|
| 02/04/2026 | Date of event requiring the filing |
| 03/17/2026 | Date of outstanding share count reference |
| 03/30/2026 | Date of Issuer's Annual Report on Form 10-K |
| 03/31/2026 | Reference date for option exercisability |
| 05/13/2026 | Date of filing |
Keywords
Eikon Therapeutics, Roger Perlmutter, Schedule 13G, Beneficial Ownership, Biotech, Insider Holdings
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.